新辅助免疫治疗在可切除非小细胞肺癌中的应用前景

doi:10.3969/j.issn.1006-7795.2021.05.027

摘要/Abstract

摘要： 可切除非小细胞肺癌作为一种潜在的可治愈性疾病,接受根治性手术或辅以化学药物治疗及放射治疗(以下简称放化疗)仍是目前标准的治疗方法,但仍有部分患者术后出现局部复发和远处转移。近期研究结果显示,将免疫治疗用于新辅助治疗的初步结果令人振奋,可使20%~85%的病例获得主要病理学缓解,优于既往新辅助化疗,提示免疫检查点抑制剂在可切除非小细胞肺癌新辅助治疗应用中非常具有潜力。本文针对免疫治疗对可切除非小细胞肺癌患者的疗效、治疗中的潜在风险予以综述。随着免疫检查点抑制剂进入国家医保,新辅助免疫治疗必将为可切除非小细胞肺癌患者带来崭新的治疗模式和希望。

关键词: 非小细胞肺癌, 可切除, 免疫检查点抑制剂, 新辅助治疗

Abstract: Resectable non-small cell lung cancer (NSCLC) is known as a potentially curable disease. Radical surgery or adjuvant chemotherapy and radiotherapy is the standard treatment, but quite a few patients will have local recurrence and distant metastasis after surgery. More recent publications indicate that immune checkpoint blockade may have better potential in neoadjuvant therapy, with reported major pathological response rates of 20% to 85%, compared to chemotherapy alone. This review intends to summarize the efficacies and potential risks of neoadjuvant targeted therapy and immunotherapy in patients with NSCLC. With more and more independent research and development of immune checkpoint inhibitors listed in China,we discussed the future developments in neoadjuvant therapy.

Key words: non-small cell lung cancer, resectability, immune checkpoint inhibitors, neoadjuvant therapy

中图分类号:

R734.2

谭晓刚, 张毅. 新辅助免疫治疗在可切除非小细胞肺癌中的应用前景[J]. 首都医科大学学报, 2021, 42(5): 862-867.

Tan Xiaogang, Zhang Yi. Progress in neoadjuvant immunotherapy for resectable non-small cell lung cancer[J]. Journal of Capital Medical University, 2021, 42(5): 862-867.

参考文献

[1] Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68 (6): 394424.
[2] Burdett S, Stewart L, Auperin A, et al. Chemotherapy in nonsmallcell lung cancer: an update of an individual patient data metaanalysis[J]. J Clin Oncol, 2005, 23 (4): 924926.
[3] Betticher D C, Hsu Schmitz S F, Totsch M, et al. Mediastinal lymph node clearance after docetaxelcisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage ⅢA pN2 nonsmallcell lung cancer: a multicenter phase Ⅱ trial[J]. J Clin Oncol, 2003, 21 (9): 17521759.
[4] NSCLC Metaanalysis Collaborative Group. Preoperative chemotherapy for nonsmallcell lung cancer: a systematic review and metaanalysis of individual participant data[J]. Lancet, 2014, 383 (9928): 15611571.
[5] Forde P M, Chaft J E, Smith K N,et al. Neoadjuvant PD-1 blockade in resectable lung cancer[J]. N Engl J Med, 2018, 378(21):1976-1986.
[6] Hui R, Ozgüroglu M, Villegas A, et al. Patient-reported outcomes with durvalumab after chemoradiotherapy in stage I, unresectable non-small cell lung cancer (PACIFIC); a randomised, controlled, phase 3 study[J]. Lancet Oncol, 2019, 20(12): 1670-1680.
[7] Rusch V, Chaft J, Johnson B, et al. Neoadjuvant atezolizumab in resectable non-small cell lung cancer (NSCLC): Initial results from a multicenter study (LCMC3)[J]. J Clin Oncol, 2018, 36:8541-8541.
[8] Provencio M, Nadal E, Insa A, et al. Neoadjuvant chemo-immunotherapy for the treatment of stage ⅢA resectable non-small cell lung cancer (NSCLC)[J]: A phase II multicenter exploratory study-Final data of patients who underwent surgical assessment[J]. J Clin Oncol, 2019, 37 (Suppl 15): 8509.
[9] Cascone T, William W N, Weissferdt A, et al. Neoadjuvant nivolumab (N) or nivolumab plus ipilimumab (NI) for resectable non-small cell lung cancer (NSCLC)[J]. Ann Oncol, 2018, 29: vi738.
[10]Pardoll D M. The blockade of immune checkpoints in cancer immunotherapy[J]. Nat Rev Cancer, 2012, 12(4): 252264.
[11]Lavin Y, Kobayashi S, Leader A, et al. Innate immune landscape in early lung adenocarcinoma by paired single-cell analyses[J]. Cell, 2017, 169(4):750-765 e17.
[12]El Kadmiri M A A, Rajan A. Neoadjuvant immunotherapy for non-small cell lung cancer: can early intervention result in durable clinical benefit?[J]. J Thorac Dis, 2018, 10(Suppl 26): S3203-S3206.
[13]Gettinger S, Horn L, Jackman D, et al. Five-year follow-up of nivolumab in previously treated advanced non-small-cell lung cancer: results from the CA209-003 Study[J]. J Clin Oncol, 2018, 36(17): 1675-1684.
[14]Rosell R, GómezCodina J, Camps C, et al. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with nonsmall cell lung cancer[J]. N Engl J Med, 1994, 330(3): 153158.
[15]Bott M J, Yang S C, Park B J, et al. Initial results of pulmonary resection after neoadjuvant nivolumab in patients with resectable non-small cell lung cancer[J]. J Thorac Cardiovasc Surg, 2019, 158(1): 269-276.
[16]Rusch V, Chaft J, Johnson B, et al. MA04.09 neoadjuvant atezolizumab in resectable non-small cell lung cancer (NSCLC): updated results from a multicenter study (LCMC3)[J]. Thorac Oncol, 2018, 13(10):S369.
[17]Li N, Ying J, Tao X, et al. P1.18-06 efficacy and safety of neoadjuvant PD-1 blockade with sintilimab in resectable non-small cell lung cancer[J]. J Thorac Oncol, 2019, 14(10):S627-S628.
[18]Bar J, Urban D, Ofek E, et al. Neoadjuvant pembrolizumab (Pembro) for early stage non-small cell lung cancer (NSCLC): Updated report of a phase Ⅰ study, MK3475-223[J]. J Clin Oncol, 2019, 37(Suppl 15):8534.
[19]Shu C A, Grigg C, Chiuzan C, et al. Neoadjuvant atezolizumab + chemotherapy in resectable non-small cell lung cancer (NSCLC) [J]. J Clin Oncol, 2018, 36(Suppl 15): 8532.
[20]Cascone T, William W N, Weissferdt A, et al. Neoadjuvant nivolumab (N) or nivolumab plus ipilimumab (NI) for resectable non-small cel lung cancer (NSCLC): Clinical and correlative results from the NEOSTAR study[J]. J Clin Oncol, 2019, 37 (15_suppl): 8504-8504.
[21]Sepesi B, Cascone T, William W, et al. OAl3.06 surgical outcomes following neoadjuvant nivolumab or nivolumab plus ipilimumab in non-small cell lung cancer- NEOSTAR study[J]. J Thorac Oncol, 2019, 14(10): S241-S242.
[22]Yeh J, Marrone K A, Forde P M. Neoadjuvant and consolidation immuno oncology therapy in stage Ⅲ nonsmall cell lung cancer [J]. J Thorac Dis, 2018, 10 (Suppl 3): S451-S459.
[23]Gopalakrishnan V, Spencer C, Reuben A, et al. Abstract 2672: response to anti-PD-1 based therapy in metastatic melanoma patients is associated with the diversity and composition of the gut microbiome [J]. Cancer Res, 2017, 77 (13 Suppl): 2672.
[24]Reuss J E, Smith K N, Anagnostou V, et al. Neoadjuvant nivolumab in resectable non-small cell lung cancer: Extended follow-up and molecular markers of response[J]. J Clin Oncol, 2019, 37 (15_suppl): 8524-8524.
[25]Sa H, Song P, Ma K, et al. Perioperative targeted therapy or immunotherapy in non-small cell lung cancer[J]. Onco Targets Ther, 2019, 12(3):8151-8159.
[26]Yang C Y, Liao W Y, Ho C C, et al. Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors[J]. Eur J Cancer, 2020,124:110-122.
[27]Dong Z Y, Zhang J T, Liu S Y, et al. EGFR mutation correlates with uninflamed phenotype and weak immunogenicity, causing impaired response to PD-1 blockade in non-small cell lung cancer[J]. Oncoimmunology, 2017, 6(11): e1356145.
[28]金珊珊,束永前.中晚期非小细胞肺癌患者培美曲塞联合铂类化疗前后免疫抑制细胞检测及意义[J].中华肿瘤防治杂志,2018,25(22):1583-1587.
[29]Tazdait M, Mezquita L, Lahmar J, et al. Patterns of responses in metastatic NSCLC during PD-1 or PD-L1 inhibitor therapy: comparison of RECIST 1.1, irRECIST and iRECIST criteria[J]. Eur J Cancer, 2018, 88:38-47.
[30]Nishino M, GiobbieHurder A, Gargano M, et al. Developing a common language for tumor response to immunotherapy: immunerelated response criteria using unidimensional measurements[J]. Clin Cancer Res, 2013, 19(14): 39363943.
[31]Gettinger S, Horn L, Jackman D, et al. Five-year follow-up of nivolumab in previously treated advanced non-small-cell lung cancer: results from the CA209-003 Study[J]. J Clin Oncol, 2018, 36(17):1675-1684.
[32]Chaft J E, Rusch V, Ginsberg M S,et al. Phase II trial of neoadjuvant bevacizumab plus chemotherapy and adjuvant bevacizumab in patients with resectable nonsquamous non-small-cell lung cancers[J]. J Thorac Oncol, 2013, 8(8):1084-1090.